Literature DB >> 2807561

[Enoxacin concentrations in serum and in the wall of the colon during colorectal surgery].

M Wenzel1, F Sörgel, P Muth, H Kraeft.   

Abstract

For successful prophylaxis of postoperative infections in colorectal surgery the administered antibiotic must reach sufficiently high concentrations in plasma and gut wall. Therefore, in ten patients receiving 400 mg enoxacin orally about 2 h prior to operation (in addition to their routine perioperative intravenous prophylaxis with amoxicillin and clavulanic acid) concentrations of enoxacin were determined by HPLC in plasma (samples were taken at the beginning of operation, time of tissue sampling and each hour during the operation) and in gut wall. We found the following plasma concentrations (mean +/- S.D.): beginning of operation 2.53 ( +/- 1.07) mg/l, 1 h later 2.08 ( +/- 0.82) mg/l, 2 h later 1.60 ( +/- 0.65) mg/l. At the time of tissue sampling (on an average 185 min after the enoxacin dose) the plasma concentration was 2.27 ( +/- 1.02) mg/l, the gut wall concentration was 3.74 ( +/- 1.58) mg/kg, the ratio between the two concentrations was 1.70 ( +/- 0.27). It seems warranted to study orally administered enoxacin (in combination with an antibiotic against anaerobes) in prophylaxis of infections after colorectal surgery.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2807561     DOI: 10.1007/bf01643633

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  3 in total

1.  Association experiments with aerobic and anaerobic pathogens: a model of in-vitro susceptibility testing in mixed infections. Activity of enoxacin, clindamycin, and metronidazole.

Authors:  W R Heizmann; R Schmid; F Heilmann; H Werner
Journal:  Infection       Date:  1989 May-Jun       Impact factor: 3.553

2.  [Susceptibility of clinically important Bacteroides species against enoxacin-metronidazole and enoxacin-clindamycin combinations].

Authors:  W R Heizmann; H Werner; R Schmid
Journal:  Infection       Date:  1989       Impact factor: 3.553

3.  Enoxacin: worldwide in-vitro activity against 22451 clinical isolates.

Authors:  C Siporin; G Towse
Journal:  J Antimicrob Chemother       Date:  1984-09       Impact factor: 5.790

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.